TARRYTOWN, N.Y., June 4, 2026
Regeneron Pharmaceuticals has unveiled a broad slate of new clinical and preclinical research across its metabolic disease, rare disease, and ophthalmology pipelines, with key findings scheduled for presentation at the American Diabetes Association (ADA) 2026 Scientific Sessions and the Endocrine Society Annual Meeting (ENDO 2026). The company’s latest data showcase progress in multiple high-priority therapeutic areas, including obesity-related muscle preservation, fibrodysplasia ossificans progressiva (FOP), Graves’ disease, thyroid eye disease, and novel antibody-based therapies. Among the most significant updates are Phase 3 OPTIMA trial results for garetosmab in FOP, one of the world’s most devastating ultra-rare genetic disorders, and new findings from the Phase 2 COURAGE study evaluating trevogrumab in obesity management. The presentations reinforce Regeneron’s commitment to advancing innovative science across diseases with substantial unmet medical needs and highlight the company’s expanding role in next-generation therapeutic development.
Phase 3 Garetosmab Data Advance Rare Disease Treatment
One of the most anticipated presentations at ENDO 2026 will feature Week 56 efficacy and safety results from the Phase 3 OPTIMA trial evaluating garetosmab in fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare and severely disabling genetic disease in which muscles, tendons, and ligaments progressively transform into bone, resulting in irreversible loss of mobility and significant morbidity. Regeneron will also present preclinical research demonstrating that blocking activin A prevents the regrowth of heterotopic bone following surgical removal in animal models, providing further biological evidence supporting the therapeutic potential of garetosmab.
Additional patient-experience analyses from the OPTIMA trial will offer valuable insights into how treatment may impact quality of life for individuals living with this devastating condition. Together, these presentations underscore Regeneron’s commitment to developing transformative therapies for rare diseases that currently have limited treatment options and substantial unmet medical needs.
Metabolic Disease Research Explores Muscle Preservation in Obesity
Advertisement
At ADA 2026, Regeneron will present multiple analyses from the Phase 2 COURAGE trial, which investigates the impact of trevogrumab, an anti-GDF8 antibody, on lean muscle mass in individuals with obesity receiving semaglutide therapy. As obesity treatments increasingly focus on substantial weight reduction, preserving muscle mass has emerged as a critical area of clinical interest. Regeneron’s research aims to better understand the relationship between body composition, metabolic health, and long-term treatment outcomes. Data being presented will evaluate lean mass changes among patients with varying baseline muscle levels, while additional studies will examine advanced imaging techniques and novel body composition assessment methods.
Early preclinical findings exploring genetic pathways involved in obesity and insulin resistance will further contribute to understanding how muscle biology influences metabolic disease progression. These presentations highlight Regeneron’s strategy of combining innovative biologic therapies with emerging metabolic medicine approaches to address complex health challenges.
Expanding Pipeline Targets Graves’ Disease and Ophthalmology Innovation
Regeneron will also share early-stage research supporting a novel antibody program targeting Graves’ disease and thyroid eye disease, two autoimmune disorders driven by shared biological mechanisms. New preclinical findings demonstrate that a TSHR-blocking antibody may effectively reduce both hyperthyroidism and eye-related symptoms in disease models, supporting further clinical development. Additional laboratory studies evaluating REGN24493, a next-generation TSHR-blocking monoclonal antibody, will provide insight into the molecule’s therapeutic potential and mechanism of action. These programs represent part of Regeneron’s growing ophthalmology and autoimmune disease portfolio, aimed at addressing conditions that can significantly impact patient quality of life.
By leveraging its proprietary antibody technologies and advanced research platforms, the company continues to expand opportunities for innovative treatments across multiple disease areas. The breadth of data presented at ADA and ENDO demonstrates Regeneron’s ability to simultaneously advance programs in metabolic disease, rare genetic disorders, endocrinology, and ophthalmology, reinforcing its position as one of the biotechnology industry’s leading research-driven innovators.
Source: Regeneron press release
